According to filings with the U.S. Securities and Exchange Commission, Eumentis Therapeutics is raising $20,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Mark Tepper played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Eumentis Therapeutics
Development stage biotech company focused on novel therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases (AD, ASD, Rett Syndrome, MEF2C, etc). Lead candidate is a second generation NMDA receptor antagonist related to Namenda with novel functionality and improved efficacy in animal models of Alzheimers Disease and Autism Spectrum Disorders. We apply the latest breakthroughs in understanding key brain receptors and neurotransmitters in neuropsychiatric conditions that so far are untreatable or poorly treated by existing drug therapies. Precision medicine the right treatment for the right patient at the right time has been an unreachable ideal so far in neuropsychiatry. We think we can change that with our unique approach to biomarker-driven patient selection in Autism Spectrum Disorder. Our Tourette Syndrome therapy is highly specific for the part of the brain involved in controlling movement, so it can potentially reduce symptoms without causing unwanted side effects.

To learn more about Eumentis Therapeutics, visit http://www.eumentistx.com/

Contact:
Mark Tepper, President and Chief Executive Officer
617-413-3020
https://www.linkedin.com/in/matepper/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.